Novavax, Inc.
NVAX
$10.75
$0.676.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 64.69% | 20.27% | 9.22% | 25.92% | -30.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.69% | 20.27% | 9.22% | 25.92% | -30.65% |
| Cost of Revenue | -29.67% | -36.56% | -38.58% | -40.10% | -43.15% |
| Gross Profit | 609.29% | 237.70% | 181.73% | 587.72% | 358.33% |
| SG&A Expenses | -55.99% | -57.95% | -52.83% | -37.22% | -33.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.71% | -44.88% | -44.06% | -39.45% | -40.47% |
| Operating Income | 342.85% | 243.72% | 228.18% | 211.92% | 57.97% |
| Income Before Tax | 350.36% | 225.36% | 249.33% | 223.49% | 67.48% |
| Income Tax Expenses | -82.86% | 74.47% | 56.89% | 215.82% | 435.89% |
| Earnings from Continuing Operations | 334.83% | 219.97% | 243.65% | 220.06% | 65.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 334.83% | 219.97% | 243.65% | 220.06% | 65.60% |
| EBIT | 342.85% | 243.72% | 228.18% | 211.92% | 57.97% |
| EBITDA | 422.10% | 285.75% | 269.48% | 240.20% | 64.07% |
| EPS Basic | 323.82% | 198.38% | 198.02% | 198.04% | 77.62% |
| Normalized Basic EPS | 362.20% | 230.98% | 193.35% | 199.26% | 74.18% |
| EPS Diluted | 281.67% | 179.33% | 182.58% | 183.78% | 76.05% |
| Normalized Diluted EPS | 317.07% | 207.29% | 175.98% | 181.47% | 72.55% |
| Average Basic Shares Outstanding | 6.47% | 12.87% | 24.83% | 37.98% | 51.15% |
| Average Diluted Shares Outstanding | 8.99% | 14.92% | 26.69% | 40.90% | 50.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |